Intuitive Surgical Gets FDA Clearance Of Revised Da Vinci Xi And X Labeling On Radical Prostatectomy Based On RWE Collected From 2007-2014 That Demonstrates Overall 5- To 10-Year Survival Following Robotic-Assisted Radical Prostatectomy Is Similar To Non-Robotic Radical Prostatectomy
Portfolio Pulse from Benzinga Newsdesk
Intuitive Surgical (NASDAQ: ISRG) received FDA clearance for revised labeling of its da Vinci X and Xi systems for radical prostatectomy, based on real-world evidence showing similar long-term survival rates to non-robotic procedures.
June 05, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intuitive Surgical received FDA clearance for revised labeling of its da Vinci X and Xi systems for radical prostatectomy, based on real-world evidence showing similar long-term survival rates to non-robotic procedures.
The FDA clearance is a positive regulatory development for Intuitive Surgical, potentially boosting investor confidence and supporting the adoption of its da Vinci systems.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100